Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.31
+0.05 (0.95%)
At close: Jan 7, 2026, 4:00 PM EST
5.47
+0.16 (3.01%)
After-hours: Jan 7, 2026, 7:50 PM EST
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.45 billion as of January 7, 2026. Its market cap has increased by 283.63% in one year.
Market Cap
1.45B
Enterprise Value
1.23B
1-Year Change
283.63%
Ranking
Category
Stock Price
$5.31
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.45B, an increase of 110.67%. That is a compound annual growth rate of 15.12%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 7, 2026 | 1.45B | -3.45% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 952.72B |
| Johnson & Johnson | 493.40B |
| AbbVie | 395.77B |
| UnitedHealth Group | 316.11B |
| AstraZeneca | 293.89B |
| Merck & Co. | 270.22B |
| Novartis AG | 268.87B |
| Novo Nordisk | 253.02B |